Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers.
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...
CBL-514, the world's first investigational drug for large-area localized fat reduction, has demonstrated significant efficacy in its second and the last Phase 2b study (CBL-0205) before Phase 3.54.2% ...
The Chiefs were listed as 1.5 point favorites leading up to Sunday's 6:30 p.m. kickoff at Caesars Superdome in New Orleans, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback